Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
Abstract Introduction Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of up...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-024-01334-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572038882000896 |
|---|---|
| author | Stamatios Gregoriou Ioannis-Alexios Koumprentziotis Ileana Afroditi Kleidona Michail Bakakis Eleni Hatzidimitriou Theodora Douvali Aikaterini Tsiogka Styliani Mastraftsi Aristeidis Vaiopoulos Alexander Stratigos |
| author_facet | Stamatios Gregoriou Ioannis-Alexios Koumprentziotis Ileana Afroditi Kleidona Michail Bakakis Eleni Hatzidimitriou Theodora Douvali Aikaterini Tsiogka Styliani Mastraftsi Aristeidis Vaiopoulos Alexander Stratigos |
| author_sort | Stamatios Gregoriou |
| collection | DOAJ |
| description | Abstract Introduction Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks. Methods This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024. Clinical and patient-reported outcomes were recorded and assessed at each follow-up visit and included the eczema area severity index (EASI), investigator global assessment (IGA), scoring atopic dermatitis (SCORAD), dermatology life quality index (DLQI) and the worst pruritus numerical scale score (WP-NRS). All drug-related adverse events (AEs) were documented. Results In total, 36 patients (44.4% female) were retrospectively included. After 4 weeks of treatment, the mean EASI was reduced from 29.97 to 3.72 with 83.3/52.8/19.4% achieving EASI75/90/100 respectively. Similar reductions were observed in the DLQI, which was reduced from 20.78 to 2.92, and in the WP-NRS, from 7.78 to 1.31. Further improvements were observed at week 16, with a mean EASI of 0.75 and 96.4% of the patients achieving EASI75 and EASI90. At week 48 of treatment, EASI75/90/100 were achieved by 100/93.8/81.3% along with a mean DLQI and pruritus NRS of 0.81. All nine patients that reached the 72- and 96-week timepoints had clear skin with no pruritus. Six (16.7%) patients experienced AEs with four of them discontinuing medication; no patient discontinued because of upadacitinib inefficacy. Conclusion This long-term real-world study of patients with moderate-to-severe AD receiving upadacitinib demonstrated that treatment success (EASI75/90/100) can be achieved in a high proportion of patients by week 16 and can be maintained for up to 96 weeks along with substantial improvements in pruritus and quality of life. |
| format | Article |
| id | doaj-art-ed543bf2f5cd412eb35a1e1e284a5789 |
| institution | Kabale University |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-ed543bf2f5cd412eb35a1e1e284a57892025-02-02T12:09:42ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-01-0115122723510.1007/s13555-024-01334-6Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre StudyStamatios Gregoriou0Ioannis-Alexios Koumprentziotis1Ileana Afroditi Kleidona2Michail Bakakis3Eleni Hatzidimitriou4Theodora Douvali5Aikaterini Tsiogka6Styliani Mastraftsi7Aristeidis Vaiopoulos8Alexander Stratigos91st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of AthensAbstract Introduction Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks. Methods This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024. Clinical and patient-reported outcomes were recorded and assessed at each follow-up visit and included the eczema area severity index (EASI), investigator global assessment (IGA), scoring atopic dermatitis (SCORAD), dermatology life quality index (DLQI) and the worst pruritus numerical scale score (WP-NRS). All drug-related adverse events (AEs) were documented. Results In total, 36 patients (44.4% female) were retrospectively included. After 4 weeks of treatment, the mean EASI was reduced from 29.97 to 3.72 with 83.3/52.8/19.4% achieving EASI75/90/100 respectively. Similar reductions were observed in the DLQI, which was reduced from 20.78 to 2.92, and in the WP-NRS, from 7.78 to 1.31. Further improvements were observed at week 16, with a mean EASI of 0.75 and 96.4% of the patients achieving EASI75 and EASI90. At week 48 of treatment, EASI75/90/100 were achieved by 100/93.8/81.3% along with a mean DLQI and pruritus NRS of 0.81. All nine patients that reached the 72- and 96-week timepoints had clear skin with no pruritus. Six (16.7%) patients experienced AEs with four of them discontinuing medication; no patient discontinued because of upadacitinib inefficacy. Conclusion This long-term real-world study of patients with moderate-to-severe AD receiving upadacitinib demonstrated that treatment success (EASI75/90/100) can be achieved in a high proportion of patients by week 16 and can be maintained for up to 96 weeks along with substantial improvements in pruritus and quality of life.https://doi.org/10.1007/s13555-024-01334-6Atopic dermatitisEczemaJAK inhibitorReal-worldUpadacitinibEASI |
| spellingShingle | Stamatios Gregoriou Ioannis-Alexios Koumprentziotis Ileana Afroditi Kleidona Michail Bakakis Eleni Hatzidimitriou Theodora Douvali Aikaterini Tsiogka Styliani Mastraftsi Aristeidis Vaiopoulos Alexander Stratigos Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study Dermatology and Therapy Atopic dermatitis Eczema JAK inhibitor Real-world Upadacitinib EASI |
| title | Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study |
| title_full | Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study |
| title_fullStr | Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study |
| title_full_unstemmed | Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study |
| title_short | Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study |
| title_sort | successful achievement of demanding outcomes in upadacitinib treated atopic dermatitis patients a real world 96 week single centre study |
| topic | Atopic dermatitis Eczema JAK inhibitor Real-world Upadacitinib EASI |
| url | https://doi.org/10.1007/s13555-024-01334-6 |
| work_keys_str_mv | AT stamatiosgregoriou successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT ioannisalexioskoumprentziotis successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT ileanaafroditikleidona successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT michailbakakis successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT elenihatzidimitriou successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT theodoradouvali successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT aikaterinitsiogka successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT stylianimastraftsi successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT aristeidisvaiopoulos successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy AT alexanderstratigos successfulachievementofdemandingoutcomesinupadacitinibtreatedatopicdermatitispatientsarealworld96weeksinglecentrestudy |